• A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort
• A New Dawn in Hepatitis D Management
• A regular screening for hepatitis delta virus among chronic hepatitis B carriers improves the diagnostic of this infection and of subsequent cirrhosis development
• A Review of the Systemic Manifestations of Hepatitis B Virus Infection, Hepatitis D Virus, Hepatocellular Carcinoma, and Emerging Therapies
• Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies
• Advances in hepatitis delta research: emerging insights and future directions
• An updated assessment of hepatitis delta prevalence among adults in Canada: A meta-analysis
• Analysis of Replication, Cell Division-Mediated Spread, and HBV Envelope Protein-Dependent Pseudotyping of Three Mammalian Delta-like Agents
• Assessing the diagnostic accuracy of serological tests for hepatitis delta virus diagnosis: a systematic review and meta-analysis
• Assessment of performance and comparison of three commercial HDV RNA detection assays: implications for diagnosis and treatment monitoring
• Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies
• Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
• Bulevirtide for the treatment of hepatitis B with hepatitis D virus coinfection
• Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial
• Cell Culture Models for Hepatitis B and D Viruses Infection: Old Challenges, New Developments and Future Strategies
• Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma
• Characterizing Hepatitis Delta in Spain and the gaps in its management
• Chronic HBV and HDV infection
• Clinical Prevalence of Hepatitis D Virus Among Hepatitis B Patients in Sulaymaniyah Governorate, Northern Iraq
• Comparative analysis of human, rodent and snake deltavirus replication
• Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections
• Current perspectives of viral hepatitis
• Deciphering the Role of Post-Translational Modifications and Cellular Location of Hepatitis Delta Virus (HDV) Antigens in HDV-Mediated Liver Damage in Mice
• Delta hepatitis in Africa: epidemiological and clinical particularities
• Development of a dual channel detection system for pan-genotypic simultaneous quantification of hepatitis B and delta viruses
• Diagnosis and treatment of viral hepatitis B and D in 2024
• Dismantling Barriers to Hepatitis B and Delta Screening, Prevention, and Linkage to Care among the PWUD Community in Philadelphia
• Dynamics of Virological and Clinical Response Parameters of Bulevirtide Treatment for Hepatitis D: Real-World Data
• Editorial: Liver elastography for chronic hepatitis D-the end of liver biopsy?
• Editorial: The current challenges underlying hepatitis D virus infection
• Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide
• Efficacy of Newer Nucleos(t)ide Analogs After Hepatitis B Immunoglobulin Discontinuation Against Hepatitis B and D Recurrence in Liver Transplant Recipients
• Efficacy of Pegylated Interferon-alpha-2a in Chronic Hepatitis Delta: Experience from a Tertiary Care Hospital in Karachi
• Enrichment reveals extensive integration of hepatitis B virus DNA in hepatitis delta-infected patients
• Ergosterol peroxide blocks HDV infection as a novel entry inhibitor by targeting human NTCP receptor
• Estimating the prevalence of hepatitis delta virus infection among adults in the United States: A meta-analysis
• Evaluation of a fully automated high-throughput serology assay for detection of Hepatitis D virus antibodies
• Exosomes as Conduits: Facilitating Hepatitis B Virus-Independent Hepatitis D Virus Transmission and Propagation in Hepatocytes
• Growing Awareness: Limited Testing and Screening Bias for Hepatitis Delta Virus in Utah 2000-2021
• Hepatitis B Delta: assessment of the knowledge and practices of hepato-gastroenterologists practicing in non-academic settings in France
• Hepatitis B in Pediatric Population: Observational Retrospective Study in Romania
• Hepatitis B Vaccine: Four Decades on
• Hepatitis B Virus Infection: A Mini Review
• Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection
• Hepatitis D infection induces IFN-beta-mediated NK cell activation and TRAIL-dependent cytotoxicity
• Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity
• Hepatitis D virus reactivation in liver-transplanted patients receiving hepatitis B immunoglobulin
• Hepatitis delta testing trends in a US national cohort: An analysis of patient and provider-level predictive factors
• Hepatitis Delta Virus and Hepatocellular Carcinoma
• Hepatitis Delta Virus Reporting Requirements in the United States and Territories: A Systematic Review
• Hepatocyte Intrinsic Innate Antiviral Immunity against Hepatitis Delta Virus Infection: The Voices of Bona Fide Human Hepatocytes
• HepG2BD: A Novel and Versatile Cell Line with Inducible HDV Replication and Constitutive HBV Expression
• Highlights from the 2023 International Meeting on the Molecular Biology of Hepatitis B virus
• ICTV Virus Taxonomy Profile: <em>Kolmioviridae</em> 2024
• Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma
• Impact of anti-HDV reflex testing at HBs antigen positive discovery in a single center France: Support for primary HDV screening in France
• Independent predictors for non-alcoholic fatty liver disease in patients with treatment-naïve chronic hepatitis B
• Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses
• Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1^-/-Ldlr^-/- mice
• Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice
• Investigating the Genetic Diversity of Hepatitis Delta Virus in Hepatocellular Carcinoma (HCC): Impact on Viral Evolution and Oncogenesis in HCC
• Is there a need for universal double reflex testing of HBsAg-positive individuals for hepatitis D infection?
• Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
• Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D-Authors' reply
• Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
• Liver transplantation in viral and autoimmune liver diseases
• Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International Network
• Long-Term Treatment with Bulevirtide in Patients with Chronic Hepatitis D and Advanced Chronic Liver Disease
• Major open questions in the hepatitis B and D field - Proceedings of the inaugural International emerging hepatitis B and hepatitis D researchers workshop
• Method for Quantitative HDV RNA Detection: I, Manual Workflow (Serum and Liver Tissue) and II, Fully Automated High Throughput Workflow for Diagnostic Use
• MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment
• Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations
• Molecular determinants within the C-termini of L-HDAg that regulate hepatitis D virus replication and assembly
• Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction
• Persistence and risk factors of occult hepatitis B virus infections among antiretroviral therapy-naïve people living with HIV in Botswana
• Pharmacist-led patient education improves medication self-management and adherence in chronic hepatitis D virus patients: insights from the EXPLAIN project
• Prevalence and risk factors of transmission of hepatitis delta virus in pregnant women in the Center Region of Cameroon
• Prevalence of hepatitis B virus infection among general population of Armenia in 2021 and factors associated with it: a cross-sectional study
• Prevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study
• Prospective study of hepatitis B and D epidemiology and risk factors in Romania: A 10-year update
• Protective role of RIPK1 scaffolding against HDV-induced hepatocyte cell death and the significance of cytokines in mice
• Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods
• Recent treatment advances and practical management of hepatitis D virus
• Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D
• Risk factors associated with hepatitis D virus infection and preventive strategies in Mongolia
• Safety and efficacy of off-label bulevirtide monotherapy in HDV patients with decompensated Child-B cirrhosis - a real world case series
• Salivary Glands and Viral Pathogenesis
• Seroprevalence and Risk Factors of Hepatitis B, C and D in Adults in Trabzon, Türkiye
• Seroprevalence of hepatitis D virus in Bulgarian outpatients with history of liver dysfunction
• Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP
• The diagnostic cascade for patients with hepatitis delta infection in France, 2018-2022: A cross-sectional study
• The distinct spatiotemporal evolutionary landscape of HBV and HDV largely determines the unique epidemic features of HDV globally
• The Dynamics of the Prevalence of Acute Viral Hepatitis and the Strategies against Viral Hepatitis in Mongolia
• The Forgotten Virus, Hepatitis D: A Review of Epidemiology, Diagnosis, and Current Treatment Strategies
• Transporter Proteins as Therapeutic Drug Targets-With a Focus on SGLT2 Inhibitors
• Treatment of Hepatitis D - A Future Role for Combination Therapy
• Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort
• Understanding the Natural History of Chronic Hepatitis D: Proposal of a Model for Cost-Effectiveness Studies
• Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta
• What Is Hepatitis D Infection?